Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Netherlands Heart Journal
Published in: Netherlands Heart Journal 10/2008

01-10-2008 | original article

Complications and mid-term outcome after percutaneous patent foramen ovale closure in patients with cryptogenic stroke

Authors: J. G. L. M. Luermans, M. C. Post, H. W. M. Plokker, J. M. ten Berg, M. J. Suttorp

Published in: Netherlands Heart Journal | Issue 10/2008

Login to get access

Extract

The presence of a patent foramen ovale (PFO) with or without an atrial septal aneurysm (ASA) has been associated with cryptogenic stroke or stroke of undefined cause, especially in young adults.1-3 Paradoxical embolism through a PFO is thought to be the most likely stroke mechanism.4,5 Patients with cryptogenic stroke related to PFO, particularly those with an associated ASA, seem to be at risk for stroke recurrence.6-9 High recurrence rates of stroke or transient ischaemic attack (TIA) are reported after medical treatment.9,10 …
Literature
1.
Hausmann D, Mugge A, Becht I, Daniel WG. Diagnosis of patent foramen ovale by transesophageal echocardiography and association with cerebral and peripheral embolic events. Am J Cardiol 1992;70:668-72.
2.
Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 2000;55: 1172-9.
3.
Webster MW, Chancellor AM, Smith HJ, Swift DL, Sharpe DN, Bass NM, et al. Patent foramen ovale in young stroke patients. Lancet 1988;2:11-2.
4.
Caes FL, Van Belleghem YV, Missault LH, Coenye KE, Van Nooten GJ. Surgical treatment of impending paradoxical embolism through patent foramen ovale. Ann Thorac Surg 1995;59: 1559-61.
5.
Falk V, Walther T, Krankenberg H, Mohr FW. Trapped thrombus in a patent foramen ovale. Thorac Cardiovasc Surg 1997;45:90-2.
6.
Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002;105:2625-31.
7.
Bogousslavsky J, Garazi S, Jeanrenaud X, Aebischer N, Van Melle G. Stroke recurrence in patients with patent foramen ovale: the Lausanne Study. Lausanne Stroke with Paradoxal Embolism Study Group. Neurology 1996;46:1301-5.
8.
Mas JL, Zuber M. Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transient ischemic attack. French Study Group on Patent Foramen Ovale and Atrial Septal Aneurysm. Am Heart J 1995;130:1083-8.
9.
Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001; 345:1740-6.
10.
Homma S, DiTullio MR, Sacco RL, Sciacca RR, Mohr JP. Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale. Stroke 2004;35:2145-9.
11.
Braun M, Gliech V, Boscheri A, Schoen S, Gahn G, Reichmann H, et al. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and midterm follow-up results of three different device occluder systems. Eur Heart J 2004;25:424-30.
12.
Post MC, Van Deyk K, Budts W. Percutaneous closure of a patent foramen ovale: single-centre experience using different types of devices and mid-term outcome. Acta Cardiol 2005;60: 515-9.
13.
Wahl A, Windecker S, Meier B. Patent foramen ovale: patho-physiology and therapeutic options in symptomatic patients. Minerva Cardioangiol 2001 December;49:403-11.
14.
Windecker S, Wahl A, Chatterjee T, Garachemani A, Eberli FR, Seiler C, et al. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events. Circulation 2000;101:893-8.
15.
Martin F, Sanchez PL, Doherty E, Colon-Hernandez PJ, Delgado G, Inglessis I, et al. Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism Circulation 2002;106:1121-6.
16.
Schwerzmann M, Windecker S, Wahl A, Mehta H, Nedeltchev K, Mattle H, et al. Percutaneous closure of patent foramen ovale: impact of device design on safety and efficacy. Heart 2004;90:186-90.
17.
Khairy P, O'Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann Intern Med 2003;139:753-60.
18.
Bruch L, Parsi A, Grad MO, Rux S, Burmeister T, Krebs H, et al. Transcatheter closure of interatrial communications for secondary prevention of paradoxical embolism: single-center experience. Circulation 2002;105:2845-8.
19.
Wahl A, Meier B, Haxel B, Nedeltchev K, Arnold M, Eicher E, et al. Prognosis after percutaneous closure of patent foramen ovale for paradoxical embolism. Neurology 2001;57:1330-2.
20.
Windecker S, Wahl A, Nedeltchev K, Arnold M, Schwerzmann M, Seiler C, et al. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J Am Coll Cardiol 2004;44:750-8.
21.
de Belder MA, Tourikis L, Leech G, Camm AJ. Risk of patent foramen ovale for thromboembolic events in all age groups. Am J Cardiol 1992;69:1316-20.
22.
Di TM, Sacco RL, Gopal A, Mohr JP, Homma S. Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med 1992;117:461-5.
23.
Schwerzmann M, Wiher S, Nedeltchev K, Mattle HP, Wahl A, Seiler C, et al. Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks. Neurology 2004;62: 1399-401.
24.
Spies C, Strasheim R, Timmermanns I, Schraeder R. Patent foramen ovale closure in patients with cryptogenic thromboembolic events using the Cardia PFO occluder. Eur Heart J 2006; 27:365-71.
25.
Souteyrand G, Motreff P, Lusson JR, Rodriguez R, Geoffroy E, Dauphin C, et al. Comparison of transthoracic echocardiography using second harmonic imaging, transcranial Doppler and transesophageal echocardiography for the detection of patent foramen ovale in stroke patients. Eur J Echocardiogr 2006;7:147-54.
Metadata
Title
Complications and mid-term outcome after percutaneous patent foramen ovale closure in patients with cryptogenic stroke
Authors
J. G. L. M. Luermans
M. C. Post
H. W. M. Plokker
J. M. ten Berg
M. J. Suttorp
Publication date
01-10-2008
Publisher
Bohn Stafleu van Loghum
Published in
Netherlands Heart Journal / Issue 10/2008
Print ISSN: 1568-5888
Electronic ISSN: 1876-6250
DOI
https://doi.org/10.1007/BF03086174

Other articles of this Issue 10/2008

Netherlands Heart Journal 10/2008 Go to the issue

case report

Spontaneous coronary artery dissection: current insights and therapy

ICIN

Differences in distribution of fibrosis in the ventricles underlie dominant arrhythmia vulnerability of the right ventricle in senescent mice

imaging in cardiology

Subclinical myocardial infarction presenting as free wall rupture

Medica Antiqua

Heaven can wait - or down to earth in real time

editorial

Primary PCI: false positives versus false negatives

original article

Conditions mimicking acute ST-segment elevation myocardial infarction in patients referred for primary percutaneous coronary intervention